Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05943535 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 76 record versions are listed below. See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 160 → 165 locationsv76
  2. Study sites: 159 to 160v75
  3. Trial sites expanded: 154 → 159 locationsv74
  4. Study sites: 153 to 154v73
  5. Study sites: 152 to 153v72
Show 45 earlier versionsHide 45 earlier versions
  1. Study sites: 150 to 152v71
  2. Study sites: 148 to 150v70
  3. Study sites: 147 to 148v69
  4. Study sites: 146 to 147v68
  5. Study sites: 145 to 146v67
  6. Study sites: 141 to 145v66
  7. Study sites: 138 to 141v65
  8. Study sites: 137 to 138v64
  9. Eligibility criteria expanded, about 14 words Site details revised at 70 of 137 sitesv63 Show 1 more changeShow less
    • Site details revised at 70 of 137 sites

    See this version in full on ClinicalTrials.gov ↗

  10. Study sites: 136 to 137v62
  11. Study sites: 135 to 136v61
  12. Study sites: 132 to 135v60
  13. Study sites: 131 to 132v59
  14. Study sites: 130 to 131v58
  15. Study sites: 128 to 130v57
  16. Study sites: 127 to 128v56
  17. Study sites: 126 to 127v55
  18. Study sites: 125 to 126v54
  19. Study sites: 124 to 125v53
  20. Study sites: 122 to 124v52
  21. Study sites: 120 to 122v51
  22. Study sites: 117 to 120v50
  23. Study sites: 111 to 117v49
  24. Study sites: 106 to 111v48
  25. Study sites: 105 to 106v47
  26. Study sites: 104 to 105v46
  27. Study sites: 103 to 104v45
  28. Study sites: 102 to 103v44
  29. Study sites: 99 to 102v43
  30. Study sites: 97 to 99v42
  31. Study sites: 91 to 97v41
  32. Study sites: 90 to 91v40
  33. Study sites: 89 to 90v39
  34. Study sites: 88 to 89v38
  35. Study sites: 85 to 88v37
  36. Site contacts updated at 5 of 85 sitesv36
  37. Study sites: 82 to 85v35
  38. Study sites: 79 to 82v34
  39. Study sites: 74 to 79v33
  40. Study sites: 73 to 74v32
  41. Study sites: 72 to 73v31
  42. Study sites: 71 to 72v30
  43. Study sites: 70 to 71v29
  44. Study sites: 69 to 70v28
  45. Study sites: 64 to 69v27
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
Trial Details
NCT Number NCT05943535
Lead Sponsor United Therapeutics
Conditions Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Enrollment 698 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov